RxDoctor Payments Data

Edwin Molina, MD

Cardiovascular Disease · Ponce, PRNPI 1588014161

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (47.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Abbott at 49.9% of the total. Among cardiovascular disease clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$40,443in general payments, 2019–2025

Across 303 payments — averaging $133.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$20K
  • Pfizer$9K
  • Merck$3K
  • Boston Scientific$3K
  • Abiomed$2K
  • Medtronic$865
  • plus $3K from 11 others

What the payments were for

  • Speaking & faculty fees$10,58526%
  • Grants$19,00047%
  • Travel & lodging$2,8717%
  • Food & beverage$7,82719%
  • Education$1600%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott46$20,191
Pfizer5$8,750
Merck9$3,339
Boston Scientific95$2,869
Abiomed2$1,807
Medtronic42$865
Boehringer Ingelheim12$571
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)24$470
Johnson & Johnson22$426
E.r. Squibb & Sons, L.L.C.16$322
PBG Puerto Rico LLC16$281
Amgen5$267
Scpharmaceuticals Inc.1$125
Novartis5$88
United Therapeutics Corporation1$25
AstraZeneca1$24
Bayer Puerto Rico Inc.1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,443 in reported general payments places this provider in the 95th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$6,714
Medicare patients
25
Services billed
72

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol30$20,024
JardianceEmpagliflozin29$19,899
EntrestoSacubitril/Valsartan26$16,013
EliquisApixaban19$13,252
XareltoRivaroxaban13$7,553
Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid39$3,216
Nifedipine ErNifedipine176$2,394
Atorvastatin Calcium159$1,135
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide92$1,036
Bumetanide17$862
Losartan Potassium105$776
Enalapril Maleate33$700
Metoprolol Succinate72$698
Lisinopril91$584
Amlodipine Besylate117$566

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$24$20,02430 claims
Boehringer IngelheimJardiance$571$19,89929 claims
NovartisEntresto$88$16,01326 claims
PfizerEliquis$8,750$13,25219 claims
Johnson & JohnsonXarelto$426$7,55313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in Ponce

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →